MARKET

IMV

IMV

Imv Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5700
+0.0675
+13.43%
After Hours: 0.5310 -0.039 -6.84% 17:28 08/11 EDT
OPEN
0.5300
PREV CLOSE
0.5025
HIGH
0.5918
LOW
0.5100
VOLUME
327.81K
TURNOVER
0
52 WEEK HIGH
1.910
52 WEEK LOW
0.4550
MARKET CAP
46.89M
P/E (TTM)
-1.1126
1D
5D
1M
3M
1Y
5Y
IMV GAAP EPS of -$0.12, revenue of $0.03M
IMV press release (NASDAQ:<a hr...
Seekingalpha · 20h ago
BRIEF-IMV reports Q2 results
BRIEF-IMV reports Q2 results
Reuters · 21h ago
BRIEF-IMV Re-Establishes Its At-The-Market Facility Under Renewed Base Shelf Prospectus
BRIEF-IMV Re-Establishes Its At-The-Market Facility Under Renewed Base Shelf Prospectus
Reuters · 6d ago
IMV Re-Establishes Its At-the-Market Facility Under Renewed Base Shelf Prospectus
DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass., August 05, 2022--IMV Inc. ("IMV" or the "Company") (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hemato...
Business Wire · 6d ago
IMV Inc. to Announce Second Quarter 2022 Results and Host a Conference Call and Webcast on August 11, 2022
DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass., August 04, 2022--IMV Inc. (Nasdaq: IMV; TSX: IMV) ("IMV" or "the Company"), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematol...
Business Wire · 08/04 11:05
BRIEF-IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
BRIEF-IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Reuters · 07/08 20:20
IMV receives Nasdaq non-compliance letter
IMV (NASDAQ:IMV) <a href="https://seekingalpha.com/pr/18860004-imv-receives-nasd...
Seekingalpha · 07/08 20:14
IMV Gets Non-Compliance Notice From Nasdaq; Shares Fall After Hours
MT Newswires · 07/08 16:18
More
No Data
Learn about the latest financial forecast of IMV. Analyze the recent business situations of Imv Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average IMV stock price target is 8.31 with a high estimate of 14.00 and a low estimate of 2.250.
High14.00
Average8.31
Low2.250
Current 0.5700
EPS
Actual
Estimate
-0.11-0.08-0.06-0.03
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 44
Institutional Holdings: 10.27M
% Owned: 12.48%
Shares Outstanding: 82.27M
TypeInstitutionsShares
Increased
8
70.45K
New
3
41.80K
Decreased
13
739.82K
Sold Out
4
98.80K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.11%
Pharmaceuticals & Medical Research
-1.16%
Key Executives
Non-Executive Chairman/Independent Director
Michael Bailey
Chief Executive Officer/Director
Andrew Hall
Chief Scientific Officer
Jeremy Graff
Independent Director
Julia Gregory
Independent Director
Michael Kalos
Independent Director
Kyle Kuvalanka
Independent Director
Shermaine Tilley
Independent Director
Markus Warmuth
No Data
No Data
About IMV
IMV Inc. is a clinical-stage immuno-oncology company. The Company is focused on developing a portfolio of therapies based on DPX, an immune-educating technology platform, that is designed to inform a specific anti-tumor immune response, offering benefit to patients with solid or hematological cancers. Its lead candidate, maveropepimut-S (MVP-S) is a DPX-based immunotherapy that targets survivin-expressing cells for elimination by educated, cytotoxic T cells. Its other candidates include DPX-RSV and DPX-COVID-19. DPX-RSV is a DPX-based vaccine candidate targeting the respiratory syncytial virus (RSV) strain A. It is focused on developing DPX-COVID-19, a vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using its DPX platform. The Company is also developing maveropepimut-S for the treatment of breast and ovarian cancer, as well as for Diffuse large B-cell lymphoma (DLBCL) and other malignancies.

Webull offers kinds of Imv Inc stock information, including NASDAQ:IMV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMV stock methods without spending real money on the virtual paper trading platform.